GC Biopharma and Galux have entered a joint development agreement to create innovative antibody therapeutics targeting autoimmune diseases.

The two companies plan to initiate early-stage collaborative research to discover preclinical candidates by combining GC Biopharma’s pharmaceutical R&D capabilities with Galux’s AI-based antibody design technology.
In this collaboration, Galux will use its proprietary de novo antibody design platform to generate novel antibody candidates optimized for target proteins associated with autoimmune diseases.

GC Biopharma will experimentally validate the biological activity and developability of these designed antibodies as part of the joint research effort. In the early stage, the company will evaluate AI-derived antibody candidates, select promising candidates, and optimize them to secure differentiated drug candidates.

GC Biopharma has built extensive R&D expertise through its experience developing biologics across oncology, immunology, and rare diseases. Through this collaboration, the company aims to develop next-generation antibody-based therapeutics for autoimmune diseases, leveraging AI technology.

Galux is building its pipeline using its proprietary AI-powered antibody design platform and pursuing a strategy to expand real-world validation cases for AI-driven drug development through partnerships with Korean and foreign pharmaceutical companies. The company has recently engaged in joint drug development collaborations with Boehringer Ingelheim, Celltrion, LG Chem, HanAll Biopharma, ISU Abxis, and Y-Biologics, advancing research across multiple disease areas, including cancer and autoimmune disorders.

Through these efforts, the company has demonstrated the applicability of its technology to various modalities, including monoclonal and bispecific antibodies, and has pursued or discussed follow-up collaborations with several partners based on early joint development outcomes.

“Recently, collaborations between AI-based biotech companies and pharmaceutical firms with deep expertise in drug development have been rapidly expanding across the global pharmaceutical industry,” Galux Executive Vice President Taeyong Park said. “Galux is rapidly accumulating real-world applications of its AI-driven drug design technology through partnerships with various pharmaceutical companies. Through this collaboration with GC Biopharma, we will swiftly secure differentiated therapeutics for autoimmune diseases using AI and further solidify the innovative potential of AI-based drug development.”

Jaewook June, Head of R&D at GC Biopharma, said, “Autoimmune diseases remain an area with significant unmet medical needs. Through this joint research with Galux, we aim to validate the potential of AI-based antibody design technology and develop differentiated antibody therapeutics in the field of autoimmune diseases.”

Powered by Froala Editor